FDA Approval of MS Injection Plegridy Big Win for Biogen

Aug 19, 2014

Boston Globe

On Friday, the FDA approved Biogen’s application to market Plegridy, a new type of injectable drug for patients with relapsing-remitting multiple sclerosis.

Plegridy has the same active ingredient -- interferon beta -- as Biogen's Avonex, but an added polymer increases the exposure of the drug, allowing patients to take doses less frequently. While Avonex has to be injected into the muscle once a week, Plegridy can be taken by injection every two weeks.

The Cambridge biotech expects to woo patients away from shorter-acting interferons, and believes Plegridy has the potential to be the leading interferon on the market.

Read the Boston Globe release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments